Essex Savings Bank Purchases 665 Shares of Kenvue Inc. (NYSE:KVUE)

Essex Savings Bank boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 4.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,409 shares of the company’s stock after buying an additional 665 shares during the period. Essex Savings Bank’s holdings in Kenvue were worth $372,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Riverview Trust Co acquired a new position in shares of Kenvue in the 3rd quarter worth approximately $30,000. Fortitude Family Office LLC grew its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the period. Ashton Thomas Securities LLC bought a new stake in Kenvue in the third quarter valued at $35,000. Versant Capital Management Inc lifted its holdings in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its stake in shares of Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.0 %

Shares of KVUE opened at $20.83 on Thursday. The stock’s fifty day simple moving average is $22.50 and its 200-day simple moving average is $21.64. The firm has a market capitalization of $39.94 billion, a PE ratio of 37.87, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.31 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of recent analyst reports. Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday. Barclays upgraded shares of Kenvue to a “hold” rating in a research note on Thursday, December 12th. Jefferies Financial Group initiated coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.18.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.